Separately, Zacks Investment Research lowered Rexahn Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 10th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $13.75.
Shares of Rexahn Pharmaceuticals stock opened at $2.15 on Tuesday. Rexahn Pharmaceuticals has a twelve month low of $2.10 and a twelve month high of $2.12.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Northern Trust Corp increased its stake in Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) by 61.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,213 shares of the company’s stock after acquiring an additional 29,354 shares during the period. Northern Trust Corp owned approximately 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent SEC filing.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.